Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 2, 2013, Pages 117-122

  Rotberg, Benyamin ^a,b   Kronenberg, Sefi ^b,c   Carmel, Miri ^b   Frisch, Amos ^b   Brent, David ^d   Zalsman, Gil ^a,b   Apter, Alan ^b,c   Weizman, Abraham ^a,b  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE 2;

ADOLESCENT; ADOLESCENT DISEASE; ALLELE; ANXIETY DISORDER; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DNA POLYMORPHISM; DRUG DOSE INCREASE; DRUG RESPONSE; DYSTHYMIA; FEMALE; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; PANIC; PROMOTER REGION; RESPONSE TIME; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL PHOBIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ANXIETY DISORDERS; CHILD; CITALOPRAM; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; TRYPTOPHAN HYDROXYLASE;

EID: 84875428984     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0020     Document Type: Article

References (42)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Anonymous: Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 46:1503-1526, 2007.
3. Brown SM, Peet E, Manuck SB, Williamson DE, Dahl RE, Ferrell RE, Hariri AR: A regulatory variant of the human tryptophan hydroxylase-2 gene biases amygdale reactivity. Mol Psychiatry 10:884-888, 2005.
4. Canli T, Congdon E, Gutknecht L, Constable RT, Lesch KP: Amygdala responsiveness is modulated by tryptophan hydroxylase-2 gene variation. J Neural Transm 112:1479-1485, 2005.
5. Canli T, Congdon E, Todd Constable R, Lesch KP: Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on neural correlates of affective processing. Biol Psychol 79:118-125, 2008.
6. Canli T, Lesch KP: Long story short: The serotonin transporter in emotion regulation and social cognition. Nat Neurosci 10:1103-1109, 2007.
7. Chen GL, Vallender EJ, Miller GM: Functional characterization of the human TPH2 5' regulatory region: Untranslated region and polymorphisms modulate gene expression in vitro. Hum Genet 122:645-657, 2008.
8. Costello EJ, Egger HL, Angold A: The developmental epidemiology of anxiety disorders: Phenomenology, prevalence, and comorbidity. Child Adolesc Psychiatr Clin N Am 14:631-648, 2005.
9. Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A: Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 60:837-844, 2003.
10. Costello EJ, Pine DS, Hammen C, March JS, Plotsky PM, Weissman MM, Biederman J, Goldsmith HH, Kaufman J, Lewinsohn PM, Hellander M, Hoagwood K, Koretz DS, Nelson CA, Leckman JF: Development and natural history of mood disorders. Biol Psychiatry 52:529-542, 2002.
11. Crisafulli C, Fabbri C, Porcelli S, Drago A, Spina E, De Ronchi D, Serretti A: Pharmacogenetics of antidepressants. Front Pharmacol 2:1-21, 2011.
12. Esbjørn BH, Hoeyer M, Dyrborg J, Leth I, Kendall PC: Prevalence and co-morbidity among anxiety disorders in a national cohort of psychiatrically referred children and adolescents. J Anxiety Disord 24:866-872, 2010.
13. Frisch A, Finkel B, Michaelovsky E, Sigal M, Laor N, Weizman R: A rare short allele of the serotonin transporter promoter region (5-HTTLPR) found in an aggressive schizophrenic patient of Jewish Libyan origin. Psychiatr Genet 10:179-183, 2000.
14. Furmark T, Henningsson S, Appel L, Ahs F, Linnman C, Pissiota A, Faria V, Oreland L, Bani M, Pich EM, Eriksson E, Fredrikson M: Genotype over-diagnosis in amygdala responsiveness: affective processing in social anxiety disorder. J Psychiatry Neurosci 34:30-40, 2009.
15. Herrmann MJ, Huter T, Mu ller F, Muhlberger A, Pauli P, Reif A, Renner T, Canli T, Fallgatter AJ, Lesch KPAdditive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on emotional processing Cereb Cortex 17 1160-1163, 2007.
16. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G, Paddock S, McMahon FJ, Manji H, Lipsky RH: Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 64:783-792, 2007.
17. Ipser JC, Stein DJ, Hawkridge S, Hoppe L: Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev. 3: CD005170, 2009.
18. Kennard BD, Silva SG, Tonev S, Rohde P, Hughes JL, Vitiello B, Kratochvil CJ, Curry JF, Emslie GJ, Reinecke M, March J: Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): Acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry 48:186-195, 2009.
19. Kennard B, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, Hughes J, Feeny N, Weller E, Sweeney M, Reinecke M, Pathak S, Ginsburg G, Emslie G, March J, TADS Team: Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry 45:1404-1411, 2006.
20. Kessler RC, Avenevoli S, Ries Merikangas K: Mood disorders in children and adolescents: An epidemiologic perspective. Biol Psychiatry. 49:1002-1014, 2001.
21. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602, 2005.
22. Kraft JB, Slager SL, McGrath PJ, Hamilton SP: Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 58:374-381, 2005.
23. Kronenberg S, Apter A, Brent D, Schirman S, Melhem N, Pick N, Gothelf D, Carmel M, Frisch A, Weizman A: Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J Child Adolesc Psychopharmacol 17:741-750, 2007.
24. Lesch KP: Variation of serotonergic gene expression: Neurodevelopment and the complexity of response to psychopharmacologic drugs. Eur Neuropsychopharmacol 11:457-474, 2001.
25. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531, 1996.
26. Leonardo ED, Hen R: Anxiety as a developmental disorder. Neuropsychopharmacology 33:134-140, 2008.
27. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J, Treatment for Adolescents With Depression Study(TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 18:807-820, 2004.
28. Maron E, Tammiste A, Kallassalu K, Eller T, Vasar V, Nutt DJ, Metspalu A: Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol 19:451-456, 2009.
29. Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, Schaid DJ, Drews MS, Courson VL, Snyder KA, Black JL 3rd, Weinshilboum RM: SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 150B:341-351, 2009.
30. Nakamura M, Ueno S, Sano A, Tanabe H: The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 5:32-38, 2000.
31. Porcelli S, Fabbri C, Serretti A: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 22:239-258, 2012.
32. Pediatric OCD Treatment Study (POTS) Team: Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 292:1969-1976, 2004.
33. Ryan ND, Birmaher B, Perel JM, Dahl RE, Meyer V, al-Shabbout M, Iyengar S, Puig-Antich J: Neuroendocrine response to L-5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children. Arch Gen Psychiatry 49:843-851, 1992.
34. Scheuch K, Lautenschlager M, Grohmann M, Stahlberg S, Kirchheiner J, Zill P, Heinz A, Walther DJ, Priller J: Characterization of a functional promoter polymorphism of the human tryptophan hydroxylase 2 gene in serotonergic raphe neurons. Biol Psychiatry 62:1288-1294, 2007.
35. Schirman S, Kronenberg S, Apter A, Brent D, Melhem N, Pick N, Carmel M, Frisch A, Weizman A, Gothelf D: Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. J Neural Transm 117:139-45, 2010.
36. Serretti A, Kato M, De Ronchi D, Kinoshita T: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12:247-257, 2007.
37. Stoltenberg SF, Nag P: Description and validation of a dynamical systems model of presynaptic serotonin function: genetic variation, brain activation and impulsivity. Behav Genet 40:262-279, 2010.
38. Vitiello B: Treatment of adolescent depression: what we have come to know. Depress Anxiety 26:393-395, 2009.
39. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A: A multicenter, randomized, doubleblind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61: 1153-1162, 2004.
40. Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC: Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 359:2753-2766, 2008.
41. Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S, Klier CM, Ryan ND, Dahl RE, Wickramaratne P: Depressed adolescents grown up. JAMA 281:1707-1713, 1999.
42. Weizman A, Weizman R: Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics 1:335-341, 2000.